Cargando…
Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible
Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and national registries is mixed, the search is ongoing....
Autores principales: | Serebruany, Victor, Kim, Moo Hyun, Thevathasan, Christian, Marciniak, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524855/ https://www.ncbi.nlm.nih.gov/pubmed/31249926 http://dx.doi.org/10.1055/s-0037-1615253 |
Ejemplares similares
-
Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
por: Serebruany, Victor, et al.
Publicado: (2017) -
Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting
por: Serebruany, Victor L., et al.
Publicado: (2017) -
No mission is impossible for LHCb
por: CERN Bulletin
Publicado: (2011) -
Quality assessment in surgery: mission impossible?
por: Dindo, Daniel, et al.
Publicado: (2010) -
Prognostication in older ICU patients: mission impossible?
por: Flaatten, Hans, et al.
Publicado: (2020)